Better Buy: Pfizer vs. Bristol Myers Squibb

The times they are a-changin' for two big drugmakers. Pfizer (NYSE: PFE) will look like a much different company within a few months as it spins off Upjohn and merges the unit with Mylan. Bristol Myers Squibb (NYSE: BMY) is still integrating Celgene after acquiring the biotech in November.

Both Pfizer and BMS have seen their stocks plunge close to 30% this year then make strong rebounds. Which big pharma stock is now the better pick for long-term investors? Here's how Pfizer and Bristol Myers Squibb compare.

Image source: Getty Images.